Potential clinical value of new type of HBV serological markers ranking in the review column
10.3760/cma.j.cn501113-20190724-00268
- VernacularTitle:新型HBV血清学标志物的潜在临床价值
- Author:
Bei JIANG
1
;
Feinan LYU
;
Xiaoya ZHENG
;
Yu CAO
;
Yuqiang MI
Author Information
1. 天津市第二人民医院 天津市肝病医学研究所 300192
- Keywords:
Hepatitis B, chronic;
Hepatitis B virus;
Markers
- From:
Chinese Journal of Hepatology
2020;28(8):711-714
- CountryChina
- Language:Chinese
-
Abstract:
Liver fibrosis, liver cirrhosis and hepatocellular carcinoma caused by chronic hepatitis B are still the main diseases that seriously affect the health of Chinese population. Notably, even if serum HBV-DNA cannot be detected after treatment, many patients will still develop liver disease. Therefore, in addition to the quantitative analysis of HBV-DNA and HBsAg, other new serological markers should be sought to facilitate the selection of CHB antiviral drugs and methods, monitoring efficacy and follow-up, efficacy prediction, and the risks of viral rebound after drug withdrawal. This article focuses on three new serological markers, namely HBcrAg, HBV-RNA and anti-HBc, with a view to applying them in clinical practice.
